Dallas, Texas 03/27/2014 (FINANCIALSTRENDS) – LifeVantage Corp (NASDAQ:LFVN) is dedicated to helping many people achieve their healthy living via a combination of compelling business-opportunity & scientifically validated products. It announced that Douglas C. Robinson, their President & Chief Executive Officer will now be presenting at – 26 Annual ROTH Conference, that is to be held on March 9-12th , 2014, at Ritz- Carlton Laguna Niguel. LifeVantage Corp (NASDAQ:LFVN)’s investor presentation was held on 11 Marc, 2014.
Protandim is the company’s patented dietary-supplement that is marketed by LifeVantage Corporation (NASDAQ: LFVN which was previously LifeLine Therapeutics. The manufacturer of Protandim claim that their product can in an indirect manner, indirectly increase the antioxidant activity by up-regulating the endogenous antioxidant factors like enzymes superoxide dismutase & catalase, and the tripeptide glutathione. Like all the dietary supplements, Protandim has also not been evaluated by the United States FDA and it is not intended for diagnosing, treating, curing or preventing any disease.
LifeVantage Corp (NASDAQ:LFVN) is involved in identifying and researching & developing and in manufacturing as well as distribution of a very advanced nutraceutical -dietary supplements, including its product, Protandim. This is an Nrf2 Synergizer & its anti-aging skin care-product, LifeVantage TrueScience. LifeVantage Corp (NASDAQ:LFVN) focuses the ongoing internal- research efforts on the oxidative stress solutions, mainly activation of nuclear-factor (erythroid- derived 2)-like-2, also called Nrf2, as this relates to various health-related disorders.
LifeVantage Corp (NASDAQ:LFVN) provides products & network marketing-business opportunity to customers & independent distributors. It sells the products in the U.S, Australia, Japan, and Mexico via a network of its independent distributors, & to the preferred & retail customers. It also sells the products directly to the consumers who are in Canada, for personal consumption. As of 30 June 2012, the company held 4 patents related to the product and the 5th patent related to the Protandim product had been granted in 2012 July.
